Why is 2026 considered a turning point for clinical trial disclosure and transparency?
2026 marks the year transparency shifts from a compliance requirement to a core principle of good clinical practice (GCP). As ICH E6(R3) is implemented across major markets, transparency becomes embedded in trial design rather than addressed after the fact. Sponsors are expected to plan for global disclosure, plain‑language communication with participants, and expanded reporting obligations from day one—fundamentally changing how trials are designed, conducted, and reported.
How is artificial intelligence actually helping disclosure teams in 2026?
AI’s value in 2026 is practical, targeted, and workflow‑driven, not transformational hype. The most effective uses include:
Extracting disclosure‑relevant data from protocols and trial documents
Converting unstructured protocols into structured formats aligned with ICH M11
Generating first‑draft plain‑language summaries that reduce manual effort
Supporting multi‑jurisdictional formatting and submission requirements
Rather than replacing disclosure professionals, AI augments existing tools and processes to help teams meet expanding obligations without expanding headcount.
What should disclosure professionals prioritize now to prepare for 2026?
Key priorities include:
Building disclosure strategy into protocol design from the outset
Preparing for ICH E6(R3) implementation timelines across regions (including Singapore, Canada, the UK, and EU)
Ensuring readiness for Europe’s maturing transparency ecosystem, including PASS and EUDAMED requirements
